Recovery of normal autologous myelopoiesis after graft rejection following allogeneic bone marrow transplant for agnogenic myeloid metaplasia

Clinical and Laboratory Haematology
S AlkindiM E D Flowers

Abstract

Allogeneic hematopoietic transplantation is the only currently available therapy that has the potential to cure agnogenic myeloid metaplasia (AMM) or primary myelofibrosis (PMF). Amelioration of fibrosis and eradication of the abnormal clone is thought to occur through the repopulation of marrow by donor-derived hematopoiesis and graft-vs.-host reaction leading to graft vs. tumor effect. We report here a 50-year-old female with AMM/PMF, conditioned with busulfan and cyclophosphamide, who rejected a single locus (HLA-B) mismatched bone marrow transplant from her daughter, but recovered normal autologous hematopoiesis with disappearance of marrow fibrosis and extramedullary hematopoiesis. Variable number tandem repeats (VNTR) analysis showed a gradual loss of donor-derived hematopoietic cells with recovery of autologous hematopoiesis. This case therefore illustrates that eradication of AMM/PMF in this patient with myeloablative chemotherapy combined with a transient allogeneic effect was sufficient to suppress the abnormal stem cell clone associated with AMM/PMF with subsequent cure.

References

Dec 1, 1992·British Journal of Haematology·G J CreemersA Hagenbeek
Nov 1, 1988·American Journal of Hematology·R E SmithE J Szabo
Nov 1, 1995·Foot & Ankle International·D G Wright, R S Adelaar
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Barosi
Feb 27, 2001·Current Opinion in Oncology·B D Smith, A R Moliterno
Sep 1, 2004·Internal Medicine·David DingliAyalew Tefferi
Nov 27, 2004·Cancer·Bryan T HennessySrdan Verstovsek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.